Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.45 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.45 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.45 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.45 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.42 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29921915 | 0.80 | CHEK1 (0.53) | BMPR1BKDRBMPR1AACVR1BTGFBR1 | |
| SCHEMBL29071545 | 0.80 | CHEK1 (0.53) | BMPR1BKDRBMPR1AACVR1BTGFBR1 | |
| SCHEMBL1570038 | 0.75 | AR (0.44) | CDK2GSK3BPIK3CAMAPK10MTOR | |
| SCHEMBL3947775 | 0.75 | LMNA (0.50) | GSK3BPIK3CAPIK3CD | |
| SCHEMBL1569971 | 0.74 | CHEK1 (0.46) | LRRK2CHEK1PIK3CA | |
| SCHEMBL732740 | 0.74 | PIK3CA (0.35) | LRRK2CHEK1PDE3BPDE3APIK3CA | |
| SCHEMBL20029214 | 0.73 | BMPR1B (0.46) | BMPR1BKDRBMPR1AACVR1BTGFBR1 | |
| SCHEMBL730703 | 0.71 | LRRK2 (0.35) | KDRLRRK2PDE3BPDE3APIK3CA | |
| SCHEMBL27847540 | 0.71 | LGMN (0.46) | — | |
| SCHEMBL30875530 | 0.69 | PDE3B (0.49) | BMPR1BKDRBMPR1AACVR1BTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102123991-A | 2-arylaminoquinazolines for the treatment of proliferative diseases | NOVARTIS AG | 2011-07-13 | — | — | CN | disclosed |
| EP-2307385-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| CN-101652352-A | Quinazolines for PDK1 inhibition | NOVARTIS VACCINES & DIAGNOSTIC | 2010-02-17 | — | — | CN | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | BMPR1B 4107/4885KDR 957/4885BMPR1A 3876/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | BMPR1B 2904/4885KDR 1028/4885BMPR1A 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.